{"id":17807,"date":"2025-05-22T18:09:55","date_gmt":"2025-05-22T16:09:55","guid":{"rendered":"https:\/\/adragos-pharma.com\/?p=17807"},"modified":"2025-05-28T10:49:43","modified_gmt":"2025-05-28T08:49:43","slug":"key-considerations-for-effective-clinical-trial-material-ctm-management","status":"publish","type":"post","link":"https:\/\/adragos-pharma.com\/key-considerations-for-effective-clinical-trial-material-ctm-management\/","title":{"rendered":"Key Considerations for Effective Clinical Trial Material (CTM) Management"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Clinical trial material (CTM)<\/strong> is fundamental to the <strong>drug development process<\/strong>, acting as the bridge between laboratory research and the first evaluations of new <strong>drug products<\/strong> in <strong>human subjects<\/strong>. For <strong>pharmaceutical companies<\/strong>, understanding the essential components and best practices for <strong>manufacturing CTM<\/strong> is crucial to ensure <strong>patient safety<\/strong>, <strong>regulatory compliance<\/strong>, and reliable <strong>clinical trial outcomes<\/strong>. The following sections explore what <strong>clinical trial material<\/strong> is, how it is produced and controlled, and why meticulous planning and <strong>quality assurance<\/strong> are critical at every stage of <a rel=\"noopener noreferrer\" href=\"https:\/\/adragos-pharma.com\/clinical-trials-essential-insights-into-clinical-trial-services-for-patients\/\" target=\"_self\"><strong>clinical trials<\/strong><\/a>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>What is Clinical Trial Material (CTM) and Its Crucial Role<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Clinical trial material (CTM)<\/strong> is at the very heart of <strong>clinical research<\/strong> and <strong>drug development<\/strong>. CTM includes all forms of the <strong>drug product<\/strong>\u2014such as <strong>investigational medicinal products<\/strong>, <strong>investigational drugs<\/strong>, <strong>placebos<\/strong>, and <strong>comparators<\/strong>\u2014specifically manufactured for use in <strong>clinical trials<\/strong> on <strong>human subjects<\/strong>. These materials are prepared to meet the highest standards of <strong>safety<\/strong>, <strong>quality<\/strong>, and <strong>efficacy<\/strong>, as specified by regulatory bodies like the <strong>FDA<\/strong> and <strong>European Medicines Agency<\/strong>. At this stage, the product leaves the laboratory as <strong>trial material<\/strong> and becomes the human-ready dose tested in real-world <strong>clinical studies<\/strong>. The <strong>quality<\/strong> and reliability of CTM are pivotal for safeguarding <strong>trial participants<\/strong> and for collecting data that accurately reflects the product\u2019s therapeutic potential.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>The Complex Process of Clinical Trial Material Manufacturing<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The transition from small-scale laboratory work to <strong>clinical trial manufacturing<\/strong> involves implementing specific <strong>clinical manufacturing processes<\/strong> that introduce significant challenges. Unlike making small research batches, <strong>manufacturing clinical trial materials<\/strong> requires robust processes that adhere to <strong>cGMP guidelines<\/strong> and <strong>good manufacturing practices (GMP)<\/strong>, and following <strong>GMP guidance<\/strong>. This involves the <strong>scale up<\/strong> and manufacture of <strong>clinical trial materials<\/strong> without sacrificing consistency, managing new sources of variability, and producing enough material for multiple trial sites or <strong>large-scale clinical trials<\/strong>. The <strong>manufacturing process<\/strong> must be validated to guarantee every dose has identical composition and <strong>quality<\/strong>, supported by detailed documentation and <strong>quality control<\/strong> steps. From qualifying the equipment\u2014ensuring all equipment and materials are properly <strong>identified<\/strong> and documented\u2014to training specialized personnel and adapting workflows, every element is designed to meet <strong>strict regulatory requirements<\/strong> and ensure <strong>patient safety<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Key Steps in Planning and Execution<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">A successful CTM project always begins with <strong>proactive planning<\/strong>. This planning involves building a realistic timeline that accounts not only for <strong>drug substance production<\/strong> but also for unavoidable losses (like overfill and destructive batch sampling) and the time needed for <strong>regulatory submissions<\/strong>. Before the clinical batch is filled, advanced analytical and stability testing must demonstrate the <strong>drug product\u2019s<\/strong> robustness. Companies must <strong>identify<\/strong> and assemble a multidisciplinary team\u2014including regulatory, <strong>process development<\/strong>, and <strong>clinical manufacturing<\/strong> experts\u2014or partner with a specialized <strong>contract development and manufacturing organization (CDMO)<\/strong>. During <strong>phase I<\/strong> and <strong>II development<\/strong>, it is especially important to ensure compliance with <strong>cGMP guidelines<\/strong> and robust <strong>quality control<\/strong>, as these early stages set the foundation for later success. This collaborative approach helps companies <strong>successfully navigate<\/strong> both operational and regulatory hurdles along the way.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>The Pillars of Quality: Qualification, Validation, and Documentation<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Ensuring the <strong>quality<\/strong> and consistency of CTM relies on meticulous attention to three interconnected components: <strong>qualification<\/strong>, <strong>validation<\/strong>, and <strong>documentation<\/strong>. Qualification involves detailed checks of equipment, selection of suitable containers and <strong>packaging<\/strong>, and training manufacturing teams. Validation tackles the proof that every <strong>clinical batch<\/strong>\u2014regardless of size or complexity\u2014can be produced identically, as required for <strong>trial material<\/strong>. This often means running test batches and validating each analytical <strong>process<\/strong> step. The final pillar, <strong>documentation<\/strong>, involves creating comprehensive <strong>manufacturing records<\/strong>. Regulators and <strong>quality assurance<\/strong> teams depend on this documentation to trace every action, rationale, and outcome during the <strong>CTM manufacturing process<\/strong>, which is essential for <strong>regulatory compliance<\/strong> during all <strong>clinical phases<\/strong> and for ensuring the traceability and <strong>quality<\/strong> of the <strong>final product<\/strong>\u2014the completed, packaged, and ready-to-distribute <strong>drug formulation<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Formulations and Packaging: Addressing Unique Challenges in <\/strong>Clinical Trial Material<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Every <strong>clinical trial material manufacturing<\/strong> campaign must address the <strong>unique challenges<\/strong> posed by specialized <strong>formulations<\/strong> and <strong>packaging<\/strong> requirements. Whether producing injectables, oral liquids, solid tablets, or cutting-edge <strong>gene therapy drugs<\/strong>, the goal is to ensure <strong>patient safety<\/strong> and ease of delivery throughout the duration of <strong>clinical trials<\/strong>. The choice of <strong>packaging<\/strong>\u2014sometimes even individualized packaging for <strong>personalized medicine<\/strong> or <strong>adaptive trial designs<\/strong>\u2014can be <strong>individual patients based<\/strong>, tailoring treatments and packaging to each patient&#8217;s unique genetic, environmental, and lifestyle needs. Regulatory authorities such as the <strong>FDA<\/strong> and <strong>European Medicines Agency<\/strong> impose <strong>strict guidelines<\/strong> on packaging as well as labeling, ensuring materials remain potent and traceable all the way to the <strong>individual patient<\/strong> or trial site.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Regulatory Requirements: Navigating Compliance in Clinical Trial Material<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Regulatory requirements<\/strong> form the backbone of <strong>clinical trial material manufacturing<\/strong>, ensuring that every step of the <strong>process<\/strong>\u2014from initial production to final distribution\u2014meets the highest standards of <strong>quality<\/strong> and <strong>safety<\/strong>. Agencies such as the <strong>FDA<\/strong> and the <strong>European Medicines Agency (EMA)<\/strong> set <strong>strict guidelines<\/strong> for the manufacturing, packaging, labeling, and distribution of <strong>investigational medicinal products<\/strong>. Adhering to these <strong>good manufacturing practices (GMP)<\/strong> is not just a legal requirement; it is essential for protecting <strong>trial participants<\/strong> and maintaining the integrity of <strong>clinical research<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Successfully navigating compliance<\/strong> means understanding and implementing the latest <strong>regulatory requirements<\/strong> for <strong>clinical trial materials<\/strong>. This includes robust <strong>quality control<\/strong> procedures, meticulous record-keeping, and validated <strong>manufacturing processes<\/strong> that can withstand regulatory scrutiny. The <strong>FDA<\/strong>, for example, provides detailed <strong>guidance<\/strong> on <strong>GMP requirements<\/strong> for <strong>clinical trials<\/strong>, emphasizing the need for comprehensive documentation and consistent <strong>quality standards<\/strong> throughout the <strong>manufacturing process<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Regulatory agencies<\/strong> routinely conduct inspections to verify that manufacturers are following <strong>GMP guidelines<\/strong> and that <strong>clinical trial materials<\/strong> are suitable for <strong>human use<\/strong>. These inspections assess everything from the cleanliness of <strong>manufacturing facilities<\/strong> to the accuracy of <strong>packaging<\/strong> and labeling. <strong>Manufacturers<\/strong> must also be prepared to manage the <strong>unique challenges<\/strong> of <strong>clinical research<\/strong>, such as <strong>scaling up production<\/strong> for <strong>larger trials<\/strong> while ensuring supply chain integrity and product consistency.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">As the landscape of <strong>clinical trials<\/strong> evolves, so too do <strong>regulatory requirements<\/strong>. <strong>Manufacturers<\/strong> must stay informed about new <strong>guidance<\/strong> and adapt their processes accordingly to ensure ongoing compliance. By prioritizing <strong>regulatory requirements<\/strong> and <strong>good manufacturing practices<\/strong>, organizations can confidently deliver high-quality <strong>clinical trial materials<\/strong> that meet the expectations of both regulators and <strong>trial participants<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>The Role of CDMOs: Strategic Partnerships in Clinical Trial Supply<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><a rel=\"noopener noreferrer\" href=\"https:\/\/adragos-pharma.com\/cdmo-meaning\/\" target=\"_self\">Contract Development and Manufacturing Organizations (CDMOs)<\/a> have become indispensable partners in the <a rel=\"noopener noreferrer\" href=\"https:\/\/adragos-pharma.com\/optimizing-the-clinical-trial-supply-chain-strategies-for-success-in-pharmaceutical-research\/\" target=\"_self\"><strong>clinical trial supply chain<\/strong><\/a>, offering specialized expertise and resources for <strong>manufacturing clinical trial materials<\/strong>. These organizations provide a comprehensive suite of services, including <strong>formulation development<\/strong>, <strong>manufacturing<\/strong>, <strong>packaging<\/strong>, labeling, and distribution, all tailored to the unique demands of <strong>clinical research<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Strategic partnerships with <strong>CDMOs<\/strong> enable sponsors to <strong>successfully navigate<\/strong> the complexities of <strong>clinical trial material manufacturing<\/strong>. <strong>CDMOs<\/strong> bring deep knowledge of <strong>GMP requirements<\/strong>, <strong>regulatory guidelines<\/strong>, and <strong>quality control<\/strong> procedures, ensuring that every batch of <strong>clinical trial materials<\/strong> meets the highest standards for <strong>safety<\/strong> and <strong>efficacy<\/strong>. Their experience in managing <strong>manufacturing processes<\/strong> and <strong>scaling up production<\/strong> is particularly valuable for sponsors preparing for <strong>larger scale clinical trials<\/strong> or introducing <strong>new treatments<\/strong> such as <strong>gene therapy<\/strong> and <strong>personalized medicine<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">By leveraging the capabilities of a <strong>CDMO<\/strong>, sponsors can reduce the risk of delays, minimize supply chain disruptions, and ensure that <strong>clinical trial materials<\/strong> are manufactured and distributed in full compliance with <strong>regulatory requirements<\/strong>. <strong>CDMOs<\/strong> also offer flexible solutions for <strong>adaptive trial designs<\/strong> and <strong>targeted therapies<\/strong>, supporting the development of innovative treatments for <strong>individual patients<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Selecting the right CDMO<\/strong> is a critical decision for any clinical trial sponsor. A strong partnership can provide <strong>guidance<\/strong> on every aspect of the <strong>manufacturing process<\/strong>, from initial development to final distribution, helping sponsors to achieve their clinical and regulatory milestones efficiently and <strong>cost-effectively<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Benefits of Specialized Clinical Trial Manufacturing<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Specialized clinical trial manufacturing<\/strong> delivers a host of advantages that can significantly enhance the success of <strong>clinical trials<\/strong>. By adopting advanced <strong>manufacturing processes<\/strong>\u2014such as on-demand or bright-stock manufacturing\u2014sponsors gain increased flexibility to respond to changing trial needs, reducing the risk of supply shortages or interruptions.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">One of the key benefits of specialized manufacturing is the ability to support <strong>adaptive trial designs<\/strong> and <strong>targeted therapies<\/strong>, which are increasingly important in modern <strong>clinical research<\/strong>. These approaches allow for more personalized treatment of <strong>individual patients<\/strong>, improving both the <strong>patient experience<\/strong> and the overall effectiveness of <strong>clinical trials<\/strong>. <strong>Specialized manufacturing processes<\/strong> can also help minimize waste and optimize production, resulting in cost savings and greater efficiency.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Furthermore, specialized <strong>clinical trial manufacturing<\/strong> ensures that all materials are produced in accordance with <strong>GMP guidelines<\/strong> and <strong>regulatory requirements<\/strong>, maintaining the highest <strong>standards of quality and safety<\/strong>. This focus on <strong>quality control<\/strong> not only protects <strong>trial participants<\/strong> but also supports the generation of reliable <strong>clinical trial data<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Sponsors who embrace specialized manufacturing strategies are better positioned to meet the <strong>unique challenges<\/strong> of <strong>clinical trials<\/strong>, from managing complex supply chains to delivering innovative <strong>new medicines<\/strong>. By carefully selecting the right manufacturing approach, organizations can maximize the benefits of their <strong>clinical trial materials<\/strong> and drive successful outcomes for both <strong>patients<\/strong> and the <strong>pharmaceutical industry<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Collaboration and Cost-Effectiveness in Modern Clinical Manufacturing<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">With the increasing complexity of <strong>drug development<\/strong>, <strong>cost-effective<\/strong> planning and expert <strong>collaboration<\/strong> have never been more important. Many organizations partner with a seasoned <strong>manufacturing organization<\/strong> or <strong>CDMO<\/strong> to provide <strong>guidance<\/strong> on <strong>GMP requirements<\/strong>, <strong>scaling up<\/strong> for <strong>larger scale production<\/strong> in <strong>phase II<\/strong> or <strong>phase III clinical studies<\/strong>, and solving <strong>unique bottlenecks<\/strong> in the <strong>clinical manufacturing process<\/strong>. Integrating <strong>quality control<\/strong>, flexible production solutions, and clear lines of communication enables companies to adapt to <strong>new treatments<\/strong>, unforeseen challenges, and urgent regulatory demands. Ultimately, combining internal know-how with external expertise enhances the likelihood of <strong>success<\/strong> while controlling costs and maximizing speed to clinical milestones.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Mastering every aspect of <strong>CTM manufacturing<\/strong> is indispensable in today\u2019s <strong>pharmaceutical landscape<\/strong>. At our specialized <strong><a href=\"https:\/\/adragos-pharma.com\/jura-switzerland\/\">facility in Jura, Switzerland<\/a><\/strong>, we are experts both in clinical and commercial manufacturing. We combine advanced technology, strict cGMP compliance, and deep experience to support your projects with the highest quality and reliability\u2014helping you bring innovative therapies to patients safely and efficiently.<\/p>\n\n\n\n<div class=\"wp-block-buttons is-content-justification-center is-layout-flex wp-container-core-buttons-is-layout-fe48e5de wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link has-secondary-background-color has-background wp-element-button\" href=\"https:\/\/adragos-pharma.com\/contact-us\/?utm_campaign=Banner_Blog_Articles&amp;utm_source=blog&amp;utm_medium=organic_search\">Do you want to know more about us?<\/a><\/div>\n<\/div>\n\n\n\n<div style=\"height:44px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Frequently Asked Questions (FAQ) About Clinical Trial Material<\/strong><\/h2>\n\n\n\n<div class=\"wp-block-gutena-accordion gutena-accordion-block gutena-accordion-block-969eb1-74 is-layout-flow wp-block-gutena-accordion-is-layout-flow\" data-single=\"true\">\n<div class=\"wp-block-gutena-accordion-panel gutena-accordion-block__panel\">\n<div class=\"wp-block-gutena-accordion-panel-title gutena-accordion-block__panel-title\"><div class=\"gutena-accordion-block__panel-title-inner\">\n<h3 class=\"wp-block-heading has-text-align-left\" style=\"margin-top:0px;margin-right:0px;margin-bottom:0px;margin-left:0px\"><strong>What is clinical research material?<\/strong><\/h3>\n<div class=\"trigger-up-down\"><div class=\"horizontal\"><\/div><div class=\"vertical\"><\/div><\/div><\/div><\/div>\n\n\n\n<div class=\"wp-block-gutena-accordion-panel-content gutena-accordion-block__panel-content\"><div class=\"gutena-accordion-block__panel-content-inner\">\n<p class=\"wp-block-paragraph\" style=\"margin-top:0;margin-bottom:0\">Clinical research material includes all drug products, comparators, and placebos produced under strict guidelines expressly for safe and effective use in clinical trials.<\/p>\n<\/div><\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-gutena-accordion-panel gutena-accordion-block__panel\">\n<div class=\"wp-block-gutena-accordion-panel-title gutena-accordion-block__panel-title\"><div class=\"gutena-accordion-block__panel-title-inner\">\n<h3 class=\"wp-block-heading has-text-align-left\" style=\"margin-top:0px;margin-right:0px;margin-bottom:0px;margin-left:0px\"><strong>What is a clinical material?<\/strong><\/h3>\n<div class=\"trigger-up-down\"><div class=\"horizontal\"><\/div><div class=\"vertical\"><\/div><\/div><\/div><\/div>\n\n\n\n<div class=\"wp-block-gutena-accordion-panel-content gutena-accordion-block__panel-content\"><div class=\"gutena-accordion-block__panel-content-inner\">\n<p class=\"wp-block-paragraph\" style=\"margin-top:0;margin-bottom:0\">Clinical material is any substance\u2014such as a drug, placebo, or control\u2014made specifically for administration to human subjects within clinical studies under robust regulatory oversight.<\/p>\n<\/div><\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-gutena-accordion-panel gutena-accordion-block__panel\">\n<div class=\"wp-block-gutena-accordion-panel-title gutena-accordion-block__panel-title\"><div class=\"gutena-accordion-block__panel-title-inner\">\n<h3 class=\"wp-block-heading has-text-align-left\" style=\"margin-top:0px;margin-right:0px;margin-bottom:0px;margin-left:0px\"><strong>What is trial material?<\/strong><\/h3>\n<div class=\"trigger-up-down\"><div class=\"horizontal\"><\/div><div class=\"vertical\"><\/div><\/div><\/div><\/div>\n\n\n\n<div class=\"wp-block-gutena-accordion-panel-content gutena-accordion-block__panel-content\"><div class=\"gutena-accordion-block__panel-content-inner\">\n<p class=\"wp-block-paragraph\" style=\"margin-top:0;margin-bottom:0\">Trial material consists of investigational medicinal products, placebos, and comparators that have been manufactured, packaged, and documented to comply with regulatory standards for use in clinical trials.<\/p>\n<\/div><\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-gutena-accordion-panel gutena-accordion-block__panel\">\n<div class=\"wp-block-gutena-accordion-panel-title gutena-accordion-block__panel-title\"><div class=\"gutena-accordion-block__panel-title-inner\">\n<h3 class=\"wp-block-heading has-text-align-left\" style=\"margin-top:0px;margin-right:0px;margin-bottom:0px;margin-left:0px\"><strong><strong>What is the substance given in clinical trials?<\/strong><\/strong><\/h3>\n<div class=\"trigger-up-down\"><div class=\"horizontal\"><\/div><div class=\"vertical\"><\/div><\/div><\/div><\/div>\n\n\n\n<div class=\"wp-block-gutena-accordion-panel-content gutena-accordion-block__panel-content\"><div class=\"gutena-accordion-block__panel-content-inner\">\n<p class=\"wp-block-paragraph\" style=\"margin-top:0;margin-bottom:0\">This is most commonly the investigational drug or investigational medicinal product (IMP), occasionally paired with a placebo or comparator, administered to patients to test safety, quality, and efficacy as required by the trial\u2019s design.<\/p>\n<\/div><\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Clinical trial material (CTM) is fundamental to the drug development process, acting as the bridge between laboratory research and the first evaluations of new drug products in human subjects. For pharmaceutical companies, understanding the essential components and best practices for [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":14415,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","inline_featured_image":false,"footnotes":""},"categories":[13],"tags":[],"topics":[],"locations":[],"experts":[],"class_list":["post-17807","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"_links":{"self":[{"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/posts\/17807","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/comments?post=17807"}],"version-history":[{"count":5,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/posts\/17807\/revisions"}],"predecessor-version":[{"id":18412,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/posts\/17807\/revisions\/18412"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/media\/14415"}],"wp:attachment":[{"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/media?parent=17807"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/categories?post=17807"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/tags?post=17807"},{"taxonomy":"topics","embeddable":true,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/topics?post=17807"},{"taxonomy":"locations","embeddable":true,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/locations?post=17807"},{"taxonomy":"experts","embeddable":true,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/experts?post=17807"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}